Tempus AI announces six rare cancer research abstracts for 2026 CTOS meeting
TEM•Tempus AI will present six research abstracts at the Connective Tissue Oncology Society annual meeting in Seoul from Nov. 18-21, 2026, including findings on gastrointestinal stromal tumor risk groups and a molecular signature that may indicate temozolomide sensitivity.
1. Research abstracts
Tempus AI will present six research abstracts at the Connective Tissue Oncology Society annual meeting in Seoul from Nov. 18-21, 2026. One study identifies gastrointestinal stromal tumor risk groups that predict prognosis better than clinical or molecular variables; another finds a molecular signature in some SDH-deficient gastrointestinal stromal tumors that suggests potential sensitivity to temozolomide.
